Breast Cancer: KOL Insight

Breast Cancer: KOL Insight

Code: FW-21072016-41 | Published: May-2016 | Pages: 0 | FirstWord
Price :

* Required Fields



Targeted therapies deliver on promise to transform breast cancer treatment

Targeted therapies continue to transform breast cancer treatment—branching out into new settings, targeting new patient populations, and in some cases upending entire treatment algorithms. Which ones will have the biggest impact on the market as pipeline drugs gain approval?

Find out in FirstWord’s new report, KOL Insight: Breast Cancer.

Packed with insights from 12 key opinion leaders (KOLs) in North America and Europe, the report covers 22 treatments (6 currently marketed and 16 in the pipeline) for 3 major types of breast cancer:

HER2+: Discover which clinical trials will decide whether established drugs are approved for use in new settings.
HER2-/HR+: Learn how dethroning the dominant drug has ushered in a new era of competition and innovation
Triple-negative (TNBC): The first targeted therapies are nearing approval. Find out which patients will benefit first.
“In breast cancer, we are at the helm of trying to identify who is going to benefit.”- US KOL

Expert insight into the breast cancer treatment landscape

The report covers 6 marketed drugs and 16 pipeline therapies for 3 major types of breast cancer:

Recently Marketed Drugs

HER2 receptor-positive breast cancer (HER2+)

Herceptin (trastuzumab; Genentech/Roche/Chugai): How will the approval of biosimilar trastuzumab affect the way oncologists prescribe Herceptin?
Kadcyla (ado-trastuzumab emtansine; Genentech/Roche/Chugai): Have the MARIANNE trial results changed the way Kadcyla is prescribed? How have they influenced KOLs’ views of subsequent trials?
Perjeta (pertuzumab; Genentech/Roche/Chugai): How do KOLs view the decision to approve Perjeta for neoadjuvant use based on pCR? Do they expect it to influence future approvals?
Tykerb (lapatinib; Novartis): Are alternative treatments limiting use of Tykerb? Which patient population can still benefit from it?

HER2 receptor-negative and hormone receptor-positive breast cancer (HER2-/HR+)

Afinitor (everolimus; Novartis): How has uptake of Ibrance changed Afinitor’s place in the treatment paradigm? What therapeutic sequencing questions have arisen as a result?
Ibrance (palbociclib; Pfizer): Is Ibrance becoming the new standard of care? How will the PALLAS and PENELOPE studies affect its prospects in adjuvant and post neoadjuvant settings?

Pipeline Drugs

HER2 receptor-positive breast cancer (HER2+)

Gilotrif/Giotrif (afatinib; Boehringer Ingelheim): What will decide afatinib’s approval for breast cancer treatment? Where will it be positioned relative to Kadcyla and Tykerb?
neratinib (PB 272; Puma Biotechnology/Pfizer): How do KOLs view neratinib’s side effects profile, and how will that affect uptake?
margetuximab (MGAH 22; MacroGenics): Early data from the SOPHIA trials has generated interest in margetuximab. What key finding is driving KOLs’ optimism?

HER2 receptor-negative and hormone receptor-positive breast cancer (HER2-/HR+)

abemaciclib (LY 2835219; Eli Lilly): What important advantage do KOLs say abemaciclib offers, and which patient population stands to benefit the most?
ribociclib (LEE 011; Novartis/Astex ): How do KOLs view ribociclib’s potential as part of a combination treatment with PI3K inhibitors?
buparlisib (BKM 120; Novartis): Do KOLs think buparlisib is likely to be approved? What factors will determine its prospects?
taselisib (GDC 0032; Roche/Genentech): KOLs say taselisib may offer an advantage over pan-PI3K inhibitors like buparlisib. What is it?
alpelisib (BYL 719; Novartis): What important concerns about treatment sequencing will affect use of all PI3K inhibitors, including alpelisib?
entinostat (SNDX 275; Syndax Pharmaceuticals): Where in the treatment paradigm is entinostat likely to be positioned relative to CDK4/6 inhibitors and PI3K inhibitors?
NeuVax (nelipepimut-S; Galena Biopharma): How do KOLs view the potential of immunotherapies in general, and NeuVax specifically, to treat breast cancer?

Triple-negative breast cancer (TNBC)

niraparib (MK 4827; Merck & Co.; Tesaro): Are KOLs in favour of combining niraparib with a checkpoint inhibitor?
veliparib (ABT 888; AbbVie): What do KOLs expect the Phase III BRIGHTNESS trial to demonstrate?
talazoparib (BMN 673; Medivation): Are KOLs optimistic about the results of the Phase II ABRAZO trial? Why do they expect further clinical trials for talzoparib to take a long time?
Lynparza (olaparib, AZD 2281; AstraZeneca): What kind of efficacy has Lynparza demonstrated in Phase I and II trials to date?
Keytruda (pembrolizumab, MK 3475; Merck & Co.): How do KOLs view potential combinations of Keytruda and a PARP inhibitor? Which PARP inhibitor is the most likely choice?
atezolizumab (MPDL 3280A; Roche): How do atezolizumab’s Phase I trial results compare to Keytruda’s. What do KOLs expect the Phase III Impassion130 study to show?

Top Takeaways

Roche strengthening its hold on HER2+ treatment: With 3 marketed HER2+ treatments already in its portfolio, Roche is focused on expanding their use. What are their prospects in the adjuvant and neoadjuvant settings?
Trials will decide the HER2+ landscape: From KATHERINE and APHINITY to ExteNET, NALA, SOPHIA, etc., learn which clinical trials will decide whether marketed therapies gain approval in new settings, and whether challengers emerge from the pipeline.
Questions about biosimilar trastuzumab: Find out whether KOLs are likely to adopt biosimilar trastuzumab, what they expect from manufacturers, and how much influence payers will have on their decisions.
Ibrance opened the floodgates for new HER2-/HR+ drugs: Can any of the several CDK4/6 inhibitors and PI3K inhibitors in the pipeline overcome Ibrance’s first to market advantage?
Sequencing is a key concern: With Ibrance pushing Afinitor down the HER2-/HR+ treatment algorithm, and new therapies on the way, what are KOLs concerns about efficacy and optimal therapeutic sequencing?
Targeted therapies finally on the horizon for TNBC: With chemotherapy still the only treatment for triple-negative breast cancer, how do KOLs feel about new PARP- and checkpoint inhibitors in the pipeline?
TNBC is a “different disease”: KOLs say that treating triple-negative breast cancer isn’t the same as treating other types. What will help them identify patients and treat the disease more effectively?

Themes Explored

Treatment algorithms in flux: KOLs expect significant changes in the near term, especially in HER2-/HR+ treatment, where Afinitor has been relegated to late line use and competition is heating up, and TNBC treatment, where the first targeted therapies are nearing approval.
Patient identification is the next big challenge: This is especially true in TNBC treatment, but even in HER2+ and HER2-/HR+ treatment, KOLs say that several drugs may be effective in niche populations, and point to a large unmet need for better patient identification.
Pipeline drugs face a slow climb: Few pipeline drugs will see Ibrance’s meteoric rise. KOLs expect several new therapies to debut as late line metastatic treatments, and slowly make their way up the treatment paradigm and into adjuvant and neoadjuvant settings.

A report based on expert knowledge

Key Opinion Leaders Interviewed for This Report

North American KOLs

Prof Catherine Azar, MD; Clinical Associate Professor of Medicine, University of Arizona, Tucson, AZ
Prof Ruta D. Rao, MD; Associate Professor of Medicine, Rush University Medical Center, Chicago, IL
Prof Adam M. Brufsky, MD, PhD; Professor of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
Prof Charles Vogel, MD; Professor of Clinical Medicine, Division of Haematology/Oncology, Miller School of Medicine, University of Miami, Miami, FL
Anonymous, US KOL; Assistant Professor of Clinical Medicine at a leading US institute
Anonymous, US KOL; Medical Oncologist specialising in breast cancer at a leading US institute

European KOLs

Dr John Conibear, MBBCh, BSc, MSc, MRCP, FRCR; Consultant Oncologist, The Holly Private Hospital, Essex, UK
Dr Richard Baird, MBBS, MA, MRCP, PhD; Academic Consultant in Breast Cancer Therapeutics, Cambridge University Hospitals, Cambridge, UK
Dr R.J. Salmon; Surgical Oncologist, Institut Curie Hospital, Paris, France
Dr Mahasti Saghatchian; Medical Oncologist Specialist in breast cancer, Institut Curie Gustave Roussy, Villejuif, France
Anonymous, German KOL; Professor of Oncology and Lead Consultant at a university oncology hospital
Anonymous, German KOL; Head of Oncology at a leading German university hospital

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Table of Contents

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.


There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare

Our Clients